Microtiter plates

Manufactured by PerkinElmer

Sourced in United States

Microtiter plates are flat laboratory dishes with multiple wells used for various assays and experiments. They are designed to hold small volumes of liquid samples or reagents, allowing for the simultaneous testing and analysis of multiple samples. Microtiter plates come in a variety of well formats and sizes to accommodate different experimental needs.

Automatically generated - may contain errors

Lab products found in correlation

Multi wavelength cell scoring module, by Molecular Devices (2 mentions) Metaexpress image analysis software, by Molecular Devices (2 mentions) Enspire alpha microplate reader, by PerkinElmer (1 mentions) Alexa 488 secondary antibody, by Thermo Fisher Scientific (1 mentions) Alexa 647 secondary antibodies, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

Microtiter plate reader (15 citations) Envision microtiter plate reader (5 citations) Victor microtiter plate fluorimeter (5 citations) OptiPlate microtiter plates (3 citations) White 96-well microtiter plates (2 citations) Black 96-well microtiter plate (2 citations) 384‐CellCarrier microtiter plate (2 citations) VICTOR microtiter plate fluorometer (2 citations) EnSpire microtiter plate spectrophotometer (1 citations)

3 protocols using microtiter plates

AlphaLISA Immunoassay for Serum Antibody Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum antibody levels of candidate antigens between the patient group and HD group were compared using the AlphaLISA^® immunoassay. Briefly, 2.5 μl of serum diluted 1:100 with AlphaLISA^® ImmunoAssay Buffer (Perkins Elmer, Waltham, MA, USA) and 2.5 μl GST or GST-fusion protein (10 μg/mL) was placed in a 384-well microtiter plates (Perkin Elmer). The mixture was incubated for at least 3 h at room temperature. Then, anti-human IgG Acceptor Beads (2.5 μl of 40 μg/ml) and Glutathione Donor Beads (2.5 μl of 40 μg/ml) were added, followed by a 14-day incubation. The plate was read using EnSpire Alpha microplate reader (Perkin Elmer). Serum antibody levels against the GST-fusion proteins were determined by subtracting the alpha counts for GST protein from the alpha counts for the GST-fusion proteins.

Hontani K., Tsuchikawa T., Hiwasa T., Nakamura T., Ueno T., Kushibiki T., Takahashi M., Inoko K., Takano H., Takeuchi S., Dosaka-Akita H., Kuwatani M., Sakamoto N., Hatanaka Y., Mitsuhashi T., Shimada H., Shichinohe T, & Hirano S. (2017). Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors. Oncotarget, 8(63), 106206-106221.

+ Open protocol

+ Expand

High-Throughput Melanoma Phenotypic Screening

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Approximately 500 cells from each biopsy were seeded in each well of 1,536-well microtiter plates (PerkinElmer) and incubated overnight. Combinatorial drug library was pin-transferred to the seeded plates as previously described (8 (link)). Plates were incubated for 96 hours, fixed in 4% formaldehyde, washed in PBS containing 0.1% Triton (PBST), and incubated overnight with antibodies (1:200) to S100 (Dako). The plates were then washed twice, incubated with Alexa 488 secondary antibodies (1:1000, Life Technologies) and DAPI 2–16 hours, and washed with PBST. Plates were then imaged using the CellWorX high-throughput microscope (Applied Precision Inc.) and nuclei and cells with S100 staining were counted with the Multi-Wavelength Cell Scoring module of the MetaExpress image analysis software (Molecular Devices). Representative control well images from each sample were manually reviewed to confirm S100 staining corresponded to cells with melanoma morphology. Technical replicates were averaged. Where replicates were available, Z’ scores were calculated (19 (link)), varying from 0.15 for CBRC029 to 0.58 for CBRC056.

Friedman A.A., Xia Y., Trippa L., Le L.P., Igras V., Frederick D.T., Wargo J.A., Tanabe K.K., Lawrence D.P., Neuberg D.S., Flaherty K.T, & Fisher D.E. (2017). Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(16), 4680-4692.

+ Open protocol

+ Expand

High-throughput Apoptosis Screening Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Approximately 250 cells per well for each cell line were seeded in each well of 1,536-well microtiter plates (PerkinElmer) and incubated overnight. Combinatorial drug library was prepared as 300X stocks in 384 well plate and 20nL pin-transferred to 1,536-well plates. Plates were incubated for 72 hours and fixed in 4% formaldehyde, washed in PBS containing 0.1% Triton, and incubated overnight with antibodies (1:500) to cleaved PARP (above). The plates were then washed twice, incubated with Alexa 647 secondary antibodies (1:1000, Life Technologies) and DAPI 2–16 hours, and washed with PBST. Plates were then imaged using the Cellworx high-throughput microscope (Applied Precision Inc.) and counting nuclei and cells with cPARP staining with the Multi-Wavelength Cell Scoring module of the MetaExpress image analysis software (Molecular Devices). Z’ values were between 0.8–0.9 for most cell lines.

Friedman A.A., Amzallag A., Pruteanu-Malinici I., Baniya S., Cooper Z.A., Piris A., Hargreaves L., Igras V., Frederick D.T., Lawrence D.P., Haber D.A., Flaherty K.T., Wargo J.A., Ramaswamy S., Benes C.H, & Fisher D.E. (2015). Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS ONE, 10(10), e0140310.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!